Добірка наукової літератури з теми "Parkison’s disease"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Parkison’s disease".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Parkison’s disease"
1
Burke, Sarah Elizabeth, Immanuel B. H. Samuel, Qing Zhou, Benzi Kluger, Catherine Price, and Mingzhou Ding. "2210." Journal of Clinical and Translational Science 1, S1 (September 2017): 59. http://dx.doi.org/10.1017/cts.2017.210.
Повний текст джерелаАнотація:
OBJECTIVES/SPECIFIC AIMS: Identify objective neurological substrates of cognitive fatigue in Parkinson’s disease and in aging. METHODS/STUDY POPULATION: Structural and diffusion MRI. Behavioral assessments for aged adults and Parkinson’s disease. RESULTS/ANTICIPATED RESULTS: Gray and white matter deficits that correlate with deficits in the basal ganglia for fatigued Parkinson’s disease patients Versus anterior cingulate cortex in healthy aged adults with fatigue. DISCUSSION/SIGNIFICANCE OF IMPACT: Over 50% of patients with Parkison’s disease and 38% of healthy older adults suffer from cognitive fatigue. However, diagnostics are limited to subjective surveys and there are no treatments for either population. Therefore, objective measures are greatly needed for better diagnosis and development of treatment targets.
2
Chuma, Takayo. "Rehabilitation Medicine for Patients with Parkison's Disease." Japanese Journal of Rehabilitation Medicine 58, no. 3 (March 18, 2021): 303–11. http://dx.doi.org/10.2490/jjrmc.58.303.
Повний текст джерела
3
Chuma, Takayo. "Rehabilitation Medicine for Patients with Parkison's Disease." Japanese Journal of Rehabilitation Medicine 56, no. 3 (March 18, 2019): 190–94. http://dx.doi.org/10.2490/jjrmc.56.190.
Повний текст джерела
4
Juncos, Jorge, Lisa Aranitis, Charles Nemeroff, Dennis Sweitzer, and Paul Yeung. "QUETIAPINE IMPROVES PSYCHOTIC SYMPTOMS ASSOCIATED WITH PARKISON's DISEASE." American Journal of Geriatric Psychiatry 7 (September 1999): 45. http://dx.doi.org/10.1097/00019442-199911001-00132.
Повний текст джерела
5
Marek, Kenneth, Danna Jennings, Gilles Tamagnan, and John Seibyl. "Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression." Annals of Neurology 64, S2 (January 6, 2009): S111—S121. http://dx.doi.org/10.1002/ana.21602.
Повний текст джерела
6
Hagenmüller, F., and M. Classen. "Motility of Oddi's Sphincter in Parkison's Disease, Progressive Systemic Sclerosis, and Achalasia." Endoscopy 20, S 1 (September 1988): 189–92. http://dx.doi.org/10.1055/s-2007-1018174.
Повний текст джерела
7
Murdoch, B. "2.353 TREATMENT OF ARTICULATORY DYSFUNCTION IN PARKISON'S DISEASE USING REPETATIVE TRANSCRANIAL MAGNETIC STIMULATION." Parkinsonism & Related Disorders 18 (January 2012): S154. http://dx.doi.org/10.1016/s1353-8020(11)70675-7.
Повний текст джерела
8
Siniscalchi, Antonio, Luca Gallelli, Nicola B. Mercuri, Guido Ferreri Ibbadu, and Giovambattista De Sarro. "Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa." Nutritional Neuroscience 9, no. 1-2 (February 2006): 11–16. http://dx.doi.org/10.1080/10284150600583446.
Повний текст джерела
9
Kyuhou, Shin-ichi. "Preventive effects of phytoestrogens on the paraquat-induced toxicities in the cellular model of Parkison disease." Neuroscience Research 58 (January 2007): S234. http://dx.doi.org/10.1016/j.neures.2007.06.545.
Повний текст джерела
10
Štuhec, Matej. "Memantine associated with parkisonism in a patient with Alzheimer's disease: A case study and the review of the literature." Anali PAZU 5, no. 1-2 (June 7, 2022): 6–9. http://dx.doi.org/10.18690/analipazu.5.1-2.6-9.2015.
Повний текст джерелаАнотація:
The positive effect of memantine on parkinsonism has been reported widely, but there have not been reports in the literature of parkinsonism, tremor and bradykinesis, induced by memantine, in an Alzheimer's patient, who did not have Parkinson's disease or a history of antipsychotic agents. In this case study, we report parkinsonism, tremor and night bradykinesis induced by memantine use (5 mg daily) in a 83-year-old Slovenian female patient. After memantine discontinuation, suggested by a clinical pharmacist specialist, and switching to donepezil 5 mg, the adverse drug reactions disappeared the next day. This case study may serve to help clinicians and clinical pharmacists distinguish memantine-induced parkinsonism from more serious conditions.
Дисертації з теми "Parkison’s disease"
1
Sharma, Manu. "Genetic epidemilogy of Parkison disease." [S.l. : s.n.], 2008.
Знайти повний текст джерела
2
Bindoff, L. A. "Defects of mitochondrial oxidations." Thesis, University of Newcastle Upon Tyne, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241373.
Повний текст джерела
3
Millot, Mathilde. "Implication de la sérotonine dans l'expression de troubles moteurs et neuropsycho-comportementaux dans la maladie de Parkison." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1100.
Повний текст джерелаАнотація:
La maladie de Parkinson (MP) se caractérise par une dégénérescence progressive et irréversible des neurones dopaminergiques de la substance noire induisant une perte de dopamine (DA) dans les structures cibles. Lorsque cette perte DA se situe entre 60 % et 80 %, les patients présentent des symptômes moteurs (rigidité, tremblement, akinésie) et non-moteurs très variés (dépression, anxiété, apathie). Ces derniers apparaissent avant et/ou en même temps que les symptômes moteurs. La dopathérapie permet de contrecarrer certains symptômes, mais tous ne sont pas sensibles à cette médication. Parallèlement à la dégénérescence DA, le système sérotoninergique (5-HT) serait aussi altéré de façon précoce dans la maladie. Cette dégénérescence est liée par l’expression de symptômes moteurs et non-moteurs. Néanmoins, aucun lien causal n’a été mis en évidence entre cette lésion 5-HT et la symptomatologie parkinsonienne. Ainsi, il était primordial de déterminer le rôle de la 5-HT dans 1) l’expression des troubles moteurs et non-moteurs 2) dans la réponse au traitement sérotoninergique et dopaminergique. Nous avons utilisé un nouveau modèle animal primate ayant une lésion 5-HT (via la MDMA) puis une lésion DA (via le MPTP). Ce modèle nous permet de mettre en évidence l’impact d’une lésion 5-HT précoce dans la symptomatologie. Des approches comportementales, pharmacologiques, d’imagerie et de neuroanatomie ont été utilisées. La lésion 5-HT a induit un trouble anxieux chez les animaux lésés à la MDMA, qui ne sont pas contrecarrer avec un traitement sérotoninergique (antidépresseur). Cette lésion a également induit une sévérité et une progression plus rapide des symptômes moteurs induits par la lésion DAParkinson’s disease (PD) is characterized by a progressive and irreversible degeneration of dopaminergic (DA) neurons localized in the substantia nigra, leading to a loss of dopamine within the target structures. When the loss of DA reaches 60 to 80 %, PD patients develop a wide range of motor (rigidity, tremor, akinesia fro example) and non-motor (depression, anxiety, apathy for example) symptoms. Dopatherapy allows the reduction of symptoms expression. But some motor and non-motor symptoms are not counteracted by those DA drugs. In addition to DA degeneration, patients present an early serotonergic (5-HT) lesion. This lesion is linked to the severity of some motor and non-motor symptoms. However, there is no causal link established between 5-HT lesion and parkinsonian symptoms. Therefore, it was essential to determine the role of 5-HT 1) in the expression of motor and non-motor symptoms 2) and in the response of DA and 5-HT treatments. For that, we used a new monkey model of PD, exhibiting a 5-HT lesion (with MDMA ‘”ecstasy”)) followed by a DA lesion (with MPTP). This model allowed us to evaluate the impact of an early 5-HT lesion on parkinsonian symptoms. We used different approaches: PET imaging, pharmacology, behavioral and neuroanatomy. The MDMA-driven early 5-HT lesion induced an anxious-like behavior on MDMA treatedmonkeys. This behavioral modification was not counteracted by 5-HT drugs (antidepressant). This MDMA lesion has also increased the severity and the progression of parkinsonian symptoms induced by DA lesion with MPTP
4
Bellot, Emmanuelle. "Le colliculus supérieur dans la maladie de Parkinson : un biomarqueur possible ?" Thesis, Université Grenoble Alpes (ComUE), 2017. http://www.theses.fr/2017GREAS043/document.
Повний текст джерелаАнотація:
Certains troubles visuo-moteurs observés dès le stade précoce de la maladie de Parkinson (MP) pourraient être liés à une altération du fonctionnement d’une structure sous-corticale reliée aux ganglions de la base, le colliculus supérieur (CS). L’objectif de cette thèse a été d’explorer l’état fonctionnel du CS chez le patient parkinsonien nouvellement diagnostiqué (de novo) avant et après instauration du traitement dopaminergique, afin d’évaluer son potentiel de biomarqueur. Pour cela, un paradigme expérimental d’Imagerie par Résonance Magnétique fonctionnelle (IRMf) a été développé, permettant d’imager avec succès l’activité fonctionnelle du CS et également du corps genouillé latéral (CGL) et de l’aire visuelle primaire V1 et de moduler leur activité via l’emploi de stimulation visuelle jouant sur de très faibles niveaux de contraste (<10%). Un test de psychophysique a également été développé, permettant d’estimer la réponse perceptuelle au contraste. Nous avons dans un premier temps testé notre protocole expérimental auprès de sujets sains d’âge variable afin d’évaluer le fonctionnement de ces trois régions d’intérêt (ROIs) au cours du vieillissement normal et de différencier les effets liés à l’âge de ceux potentiellement liés à la pathologie (Etude 1). Une diminution statistiquement significative de la réponse BOLD au sein du CGL et de V1 avec l’âge a été observée, ces réponses corrélant de plus parfaitement avec les réponses perceptuelles estimées en psychophysique. Les voies magnocellulaire et parvocellulaire semblent jouer un rôle dans cette perte de sensibilité au contraste de luminance liée à l’âge. Nous avons dans un second temps testé notre protocole auprès de patients parkinsoniens de novo avant et après instauration du premier traitement dopaminergique afin d’évaluer les effets de la MP et du traitement sur le fonctionnement de nos ROIs (Etude 2). Une altération précoce du traitement du contraste a été observée au sein du CS et du CGL chez les patients parkinsoniens, non normalisée par l’instauration du traitement dopaminergique. Ces travaux de thèse ont ainsi mis en évidence un déficit fonctionnel du CS et du CGL survenant précocement durant l’évolution de la MP, confirmé par nos analyses de connectivité effective. Ces résultats pourraient favoriser l’identification de déficits liés à un dysfonctionnement sensoriel de ces structures tout comme le développement de tests paraclinique et clinique impliquant ce système pour un diagnostic plus précoce de la maladieSome visuo-motor impairments observed in the early stages of Parkinson’s disease (PD) might be related to a dysfunction of a subcortical structure connected to the basal ganglia, the superior colliculus (SC). The aim of this PhD thesis was to explore the functional state of the SC in newly diagnosed (de novo) PD patients before and after dopaminergic treatment intake, in order to evaluate the potential value of the SC functioning as a biomarker. To do this, we developed a functional Magnetic Resonance Imaging (fMRI) experimental protocol, which successfully imaged the SC and also the lateral geniculate nucleus (LGN) and primary visual area V1 functional activity and modulate their activity by using visual stimuli with low luminance contrast levels (<10%). Additionally, we estimated the perceptual response to contrast by using a psychophysical task. We tested in a first time this experimental protocol on healthy subjects with varying age in order to evaluate the effect of normal aging on the functioning of these regions of interest (ROIs) and to distinguish the effects related to age from those potentially related to the pathology (Study 1). A significant progressive decrease of the BOLD amplitude with age was observed in the LGN and V1. These data were consistent with the response functions obtained with the psychophysical task. These results indicate a significant luminance contrast sensitivity decline with age of both the magnocellular and parvocellular pathways. In a second time, we tested our protocol on de novo PD patients before and after the introduction of the first dopaminergic treatment in order to assess the effects of PD and treatment on the ROIs functioning (Study 2). Our results highlighted an early alteration of the contrast processing for the SC and LGN in PD patients, with no normalization after dopaminergic treatment introduction. These findings indicate a functional deficit of the SC and LGN that appears early in the disease course, in line with our effective connectivity analyses. These results could favor the identification of deficits linked to sensory dysfunction of these structures as well as the development of paraclinical and clinical tests involving this system for an early diagnosis of the disease
5
Ouachikh, Omar. "Effets motivationnels des agonistes dopaminergiques dans un modèle de rat ayant une lésion bilatérale de l'aire tegmentale ventrale." Thesis, Clermont-Ferrand 1, 2013. http://www.theses.fr/2013CLF1MM18.
Повний текст джерелаАнотація:
Le traitement médicamenteux de la maladie de Parkinson idiopathique (MPI) repose essentiellement,t sur la restauration de la transmission dopaminergique par la L-Dopa et par les agonistes dopaminergiques (DARAs) agissant sur les récepteurs dopaminergiques de la classe D2R et D3R. Cependant au cours du traitement apparaissent des comportements addictifs (addiction aux médicaments dopaminergiques, hyper-sexualité, addiction aux jeux, addiction aux achats impulsifs...). Ces troubles du comportement impulsifs (TCI) observés chez les patients parkinsoniens traités aux agonistes dopaminergiques ressemblent bien à ceux observés chez les utilisateurs chroniques de drogues d'abus telles que la morphine, les amphétamines ou la cocaïne. [...] Dans le but de comprendre la physiopathologie des manifestations addictives chez le patient parkinsonien, notre étude s'est proposée d'étudier les effets renforçateurs ou motivationnels des agonistes dopaminergiques chez l'animal dont l'ATV postérieur ou antérieure ont été bilatéralement lésés. Les manifestations addictives seront investies en utilisant le test de préférence de place conditionnée (PPC), un paradigme qui étudie l'effet motivationnel / renforçateur des agonistes utilisés. Une particularité de notre étude est qu'elle a été réalisée chez l'animal naïf sans être au préalable sensibilisé à une drogue d'abus. Son intérêt est de montrer l'effet direct des agonistes dopaminergiques sur le comportement recherchéNéant
6
Hsu, Shao Hsuan, and 徐紹軒. "Design of health care watch for patients with Parkison’s disease." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/46597877222652080756.
Повний текст джерелаАнотація:
碩士長庚大學
電機工程學研究所
97
As a result of medicine advances, aging population increases. The need of care in chronic is also increased .To allow limited medical resource can be used effectively, the aim of this study was to establish a long-distance Zigbee wireless network for medical care .Not only elderly but also patients can use it to measure ECG signals and record activity amount at any time at home. For Parkison’s patients, the amount of hand tremor also can be recorded. Therefore, users for the network can be well-cared, and health care providers can have a better health monitoring on the users.
7
Clemente, Francesca. "Synthesis of alkylated azasugars and their therapeutic potential against lysosomal storage and neurological disorders: the Gaucher-Parkinson case." Doctoral thesis, 2021. http://hdl.handle.net/2158/1234174.
Повний текст джерела
8
LI, Yung-Chen, and 李詠甄. "An Analysis of Survial of Parkison’s Disease and Its Complicated Dementia: A 10-Year Population-Based Study." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/51560206833873069175.
Повний текст джерелаАнотація:
碩士國立臺北護理健康大學
健康事業管理研究所
105
Background and Objective Parkinson's disease is the secondary illness among neurodegenerative diseases, however, its causes are still unclear. Besides, the past studies have shown that those who suffer from Parkinson's disease will face higher mortality rate than others. Thus, the survival factors which affect the Parkinson disease are taken more seriously. In addition to a higher risk of death, most patients would confront the complication of dementia. While, only few studies explore the hypothesis whether the risk of death is higher in Parkinson’s disease patients with dementia than those who don’t have this complication. To supplement the insufficiency, this study, aims to compare the Parkinson's disease patients with non-Parkinson's disease patients using the National Health Insurance Research Database in terms of the risk of death and make a contrast between the survival of Parkinson’s disease patients and Parkinson’s disease patients with dementia. Methods We conducted a retrospective cohort study to evaluate the Parkinson’s disease patients, non-Parkinson's disease patients, and Parkinson's disease patients with dementia in 2002. Then, we observed the survival status after controlling the demographic variables. Based on the data extracted from the National Health Insurance Research Database from 1999 to 2012, we identified 3,091 Parkinson’s disease cases and matched “gender” and “age” to select 12,104 of non-Parkinson’s disease cases. Also, we used Cox proportional hazard model to analyze (1) the survival status of Parkinson’s disease patients and non-Parkinson's disease patients (2) the survival status of Parkinson's disease patients and Parkinson’s disease patients with dementia. Results After controlling the variables of gender, age, Charlson Comorbidity Index (CCI) and urbanization level, we find that the mortality risk of Parkinson's disease is higher than non-Parkinson's disease, while the adjusted hazard ratio was 1.37 (adjusted HR = 1.37, 95% CI = 1.24-1.50); females have lower mortality risk than males, while the adjusted hazard ratio was 38% (adjusted HR = 0.62, 95% CI = 0.53-0.74); and the patients age ≥ 65 have higher mortality risk than < 65, while the adjusted hazard ratio was 3.00 (adjusted HR = 3.00, 95% CI = 2.27-3.97); CCI score 2 has higher mortality risk than CCI score 0, while the adjusted hazard ratio was 1.45 (adjusted HR = 1.45, 95% CI = 1.07-1.96). Under the controlled variables of gender, age and CCI, the data shows that those patients who suffer from dementia confronted higher mortality risk than non-dementia patients, while the adjusted hazard ratio was 1.11 (adjusted HR = 1.11, 95% CI = 0.98-1.26). Conclusion and Suggestion We observed that Parkinson's disease patients and Parkinson's disease patients with dementia show a higher mortality risk. The study results can help patients to obtain earlier intervention services and appropriate treatment according to their needs in a different phase of disease. In this way, it can slow down the occurrence of Parkinson's disease patients with disability. In addition, we expect the results can provide reference for future assessment and health care policy and also help clinical practitioners to get further assistance of guidelines for death risk assessment of Parkinson's disease.
9
Santos, Diliana Maria Barradas Rebelo dos. "Molecular and Functional Covariance Statistics demonstrate Network Reorganization in Parkison's Disease: a multimodal PET-fMRI study." Master's thesis, 2020. http://hdl.handle.net/10316/97899.
Повний текст джерелаАнотація:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de MedicinaA Doença de Parkinson (DP) é uma doença neurodegenerativa caracterizada por sintomas motores e não-motores relacionados com a perda de neurónios dopaminérgicos na substantia nigra pars compacta. Sabe-se que este desiquilíbrio afecta vários circuitos, entre os quais, o sistema oculomotor. Trabalhos anteriores demonstraram que e como a resposta hemodinâmica é afectada neste sistema e, de um modo independente, como é o seu padrão molecular. Neste trabalho, foi averiguado se existe e qual a correlação entre padrão hemodinâmico e libertação dopaminérgica, em áreas definidas. Para tal, foram recrutados participantes controlos e com DP, estes últimos com e sem medicação e, com recurso a um paradigma block-design com 2 runs (prosacadas e antisacadas, com sacadas verticais e horizontais), foram identificadas e localizadas as áreas cerebrais de interesse, de modo a estudar a relação entre o metabolismo molecular em repouso (por tomografia de emissão de positrões, PET, usando o composto sintético Raclopride, como antagonista selectivo dos receptores D2) em áreas diferentes e entre o metabolismo molecular basal e a actividade funcional (pela ressonância magnética funcional, fMRI).Esta abordagem ROI-based foi cingida a áreas encontradas funcionalmente e de acordo com a literatura (frontal eye field, parietal eye field) e segmentadas manualmente (caudado e putamen, bilateralmente). O estudo de covariâncias mostrou que, relativamente a análise unimodal (molecular), nas prossacadas, há um domínio frontal nos controlos enquanto que, nos doentes, o predomínio é parietal (ambos para caudado e/ou putamen). No que toca a antissacadas, esta conectividade estriado-cortical salienta novamente o parietal eye field como protagonista de relevo, nos doentes e nos controlos. Relativamente a análise de covariância multimodal, o grupo de doentes mostrou uma associação funcional-molecular negativa de região frontal com o putamen ao contrário da associação postiva observada no grupo controlo. A análise de follow-up demonstrou que, no subgrupo de doentes não medicados, a associação bimodal negativa entre região frontal e estriado foi verificada, concluindo que a reorganização do circuito não depende da medicação. Face aos resultados obtidos, podemos concluir que este trabalho complementa e alarga conhecimento acerca da reorganização compensatória da conectividade molecular e funcional na Doença de Parkinson.
The use of covariance statistics based on PET imaging data represents a recent approach to study the organization of brain networks. We adopted this framework and combined PET/fMRIto investigate reorganization of dopaminergic networks and their relation with functional activation plasticity. We performed molecular imaging of dopamine D2 receptors (using 11C-Raclopride) and fMRI of the oculomotor system, including the network linking striatal regions, frontal and parietal eye fields. Our block-design included prosaccades and antisaccades, allowing to identify Frontal eye field/Parietal eye field. We measured distribution volume ratio quantitative measures of D2-receptor binding and brain activity in fourteen Parkinson’s disease patients (ON/OFF subgroups) and nine healthy controls. We tested the hypothesis whether multimodal covariance statistics reflect network reorganization in Parkinson’s disease. Concerning unimodal molecular distribution volume ratio covariance across regions defined by prosaccades, we found striking striato-cortical shifts: connectivity dominated for frontal eye field in the control group while parietal eye field dominated in PD group (both for caudate/putamen).Concerning antisaccades, parietal eye field-caudate/putamen striatal-cortical connectivity dominated in Parkinson’s disease patients (only the putamen in controls). Concerning multimodal covariance statistics, a striking sign-reversal was observed: Parkinson’s disease patients showed negative frontal eye field-putamen functional-molecular associations in contrast with the positive correlations observed in controls. Follow-up analysis in off-medication Parkinson’s disease patients confirmed a negative functional-molecular correlation concerning frontal eye field and distribution volume ratio in both putamen/caudate, and vertical/horizontal prosaccades, respectively.These results provide a multimodal functional-molecular imaging correlate of network reorganization in Parkinson’s disease. It is consistent with compensatory brain activity increases/decreases in parietal eye field/frontal eye field, and the novel observation of specific disease-related negative covariance of D2 receptor and brain activity levels.
Outro - FTC - Portuguese national funding agency for science, UID/4950/2017– COMPETE, FEDER, PAC/MEDPERSYST-16428, BIGDATIMAGE, CENTRO-01-0145-FEDER-000016 financed by Centro 2020 FEDER, COMPETE
10
Santos, Diliana Maria Barradas Rebelo dos. "Molecular and Functional Covariance Statistics demonstrate Network Reorganization in Parkison's Disease: a multimodal PET-fMRI study." Master's thesis, 2020. http://hdl.handle.net/10316/97887.
Повний текст джерелаАнотація:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de MedicinaA Doença de Parkinson (DP) é uma doença neurodegenerativa caracterizada por sintomas motores e não-motores relacionados com a perda de neurónios dopaminérgicos na substantia nigra pars compacta. Sabe-se que este desiquilíbrio afecta vários circuitos, entre os quais, o sistema oculomotor. Trabalhos anteriores demonstraram que e como a resposta hemodinâmica é afectada neste sistema e, de um modo independente, como é o seu padrão molecular. Neste trabalho, foi averiguado se existe e qual a correlação entre padrão hemodinâmico e libertação dopaminérgica, em áreas definidas. Para tal, foram recrutados participantes controlos e com DP, estes últimos com e sem medicação e, com recurso a um paradigma block-design com 2 runs (prosacadas e antisacadas, com sacadas verticais e horizontais), foram identificadas e localizadas as áreas cerebrais de interesse, de modo a estudar a relação entre o metabolismo molecular em repouso (por tomografia de emissão de positrões, PET, usando o composto sintético Raclopride, como antagonista selectivo dos receptores D2) em áreas diferentes e entre o metabolismo molecular basal e a actividade funcional (pela ressonância magnética funcional, fMRI).Esta abordagem ROI-based foi cingida a áreas encontradas funcionalmente e de acordo com a literatura (frontal eye field, parietal eye field) e segmentadas manualmente (caudado e putamen, bilateralmente). O estudo de covariâncias mostrou que, relativamente a análise unimodal (molecular), nas prossacadas, há um domínio frontal nos controlos enquanto que, nos doentes, o predomínio é parietal (ambos para caudado e/ou putamen). No que toca a antissacadas, esta conectividade estriado-cortical salienta novamente o parietal eye field como protagonista de relevo, nos doentes e nos controlos. Relativamente a análise de covariância multimodal, o grupo de doentes mostrou uma associação funcional-molecular negativa de região frontal com o putamen ao contrário da associação postiva observada no grupo controlo. A análise de follow-up demonstrou que, no subgrupo de doentes não medicados, a associação bimodal negativa entre região frontal e estriado foi verificada, concluindo que a reorganização do circuito não depende da medicação. Face aos resultados obtidos, podemos concluir que este trabalho complementa e alarga conhecimento acerca da reorganização compensatória da conectividade molecular e funcional na Doença de Parkinson.
The use of covariance statistics based on PET imaging data represents a recent approach to study the organization of brain networks. We adopted this framework and combined PET/fMRIto investigate reorganization of dopaminergic networks and their relation with functional activation plasticity. We performed molecular imaging of dopamine D2 receptors (using 11C-Raclopride) and fMRI of the oculomotor system, including the network linking striatal regions, frontal and parietal eye fields. Our block-design included prosaccades and antisaccades, allowing to identify Frontal eye field/Parietal eye field. We measured distribution volume ratio quantitative measures of D2-receptor binding and brain activity in fourteen Parkinson’s disease patients (ON/OFF subgroups) and nine healthy controls. We tested the hypothesis whether multimodal covariance statistics reflect network reorganization in Parkinson’s disease. Concerning unimodal molecular distribution volume ratio covariance across regions defined by prosaccades, we found striking striato-cortical shifts: connectivity dominated for frontal eye field in the control group while parietal eye field dominated in PD group (both for caudate/putamen).Concerning antisaccades, parietal eye field-caudate/putamen striatal-cortical connectivity dominated in Parkinson’s disease patients (only the putamen in controls). Concerning multimodal covariance statistics, a striking sign-reversal was observed: Parkinson’s disease patients showed negative frontal eye field-putamen functional-molecular associations in contrast with the positive correlations observed in controls. Follow-up analysis in off-medication Parkinson’s disease patients confirmed a negative functional-molecular correlation concerning frontal eye field and distribution volume ratio in both putamen/caudate, and vertical/horizontal prosaccades, respectively.These results provide a multimodal functional-molecular imaging correlate of network reorganization in Parkinson’s disease. It is consistent with compensatory brain activity increases/decreases in parietal eye field/frontal eye field, and the novel observation of specific disease-related negative covariance of D2 receptor and brain activity levels.
Outro - FTC - Portuguese national funding agency for science, UID/4950/2017– COMPETE, FEDER, PAC/MEDPERSYST-16428, BIGDATIMAGE, CENTRO-01-0145-FEDER-000016 financed by Centro 2020 FEDER, COMPETE
Книги з теми "Parkison’s disease"
1
Lauren, Taryn. Parkison Disease Nock Down!: How to Treat Parkison Disease Without Pills. Independently Published, 2022.
Знайти повний текст джерелаТези доповідей конференцій з теми "Parkison’s disease"
1
Melo, Yuri Sena, Wesley Anderson de Souza Miranda, João Lucas De Morais Bezerra, and Thaís Bel de Oliveira Teixeira. "The effects of virtual reality on functional capacity at different stages of Parkison’s disease." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.466.
Повний текст джерелаАнотація:
Introduction: the use of virtual reality in Parkinson’s disease is a very effective therapy, as it promotes important actions for the knowledge of the motor, stimulating neuroplasticity, through visual feedback. Study design: This is a systematic review of the literature. Objective: The objective of this study was to analyze the use of reality in the rehabilitation of functional capacity in the different stages of Parkinson’s disease. Methods: this is a systematic review, carried out from January to August 2017, by means of electronic search in the databases: Pubmed, Scielo, Lilacs, Science Direct and Medline. The descriptors used were: virtual, video game, Parkinson’s, physiotherapy and rehabilitation and all the words in English. They were defined as inclusion criteria for studies that used virtual reality as treatment for patients with Parkinson’s, classifying patients in stages (I, II, III, IV and V) according to the Hoehn & Yahr scale. Literature review articles, description of virtual reality without showing the sample of statistical results and case study were excluded. Results: 7 articles were selected. After analyzing them, it was possible to observe that patients in the early stages showed improvement in perception, gait and balance. However, patients who were in other more advanced stages of the disease only improved their perception. Conclusion: patients in the early stages of clinical Parkinson’s disease have satisfactory results when compared to the advanced stages.
2
Moro-Velazquez, L., J. A. Gomez-Garcia, J. I. Godino-Llorente, J. Rusz, S. Skodda, F. Grandas, J. M. Velazquez, J. R. Orozco-Arroyave, E. Noth, and N. Dehak. "Study of the Automatic Detection of Parkison’s Disease Based on Speaker Recognition Technologies and Allophonic Distillation." In 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2018. http://dx.doi.org/10.1109/embc.2018.8512562.
Повний текст джерела